Evidence mapPaperPMID 9886743Full record

Trial reportDiabetes research and clinical practice1998

Better glycaemic control and risk reduction of diabetic complications in Type 2 diabetes: comparison with the DCCT.

L M Molyneaux, M I Constantino, M McGill, R Zilkens, D K Yue

2 registry-linked trialsAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Diabetes research and clinical practice, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02879409 naactive not recruitingstarted 2016, after this paper: background citation

Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?

Ran2016Enrolled150Registered outcomes4Posted comparisons0ConditionsDiabetes Mellitus Type 2Armsdapagliflozin, Gliclazide, human insulin, liraglutide, Metformin
Open the trial in the graph
NCT05754008 naunknown statusnot on this mapstarted 2023, after this paper: background citation

A Randomized Trial of Care Navigator to Support Younger Latinx Adults Newly Diagnosed With Type 2 Diabetes (AURORA)

TypeinterventionalSponsorKaiser PermanenteRan2023 to 2025Enrolled204ConditionsDiabetes Mellitus, Type 2ArmsAURORA Care Strategy
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 50 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Effect of renal impairment on the pharmacokinetics of exenatide.British journal of clinical pharmacology · 2007
    Trial
  4. Observational
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Cost effectiveness and cost utility of the noncoding blood glucose meter CONTOUR TS.Diabetes, metabolic syndrome and obesity : targets and therapy · 2011
    Article
  12. Article
  13. Review
  14. Race and kidney disease: the scope of the problem.Journal of the National Medical Association · 2002
    Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

L M MolyneauxDiabetes Center of Royal Prince Alfred Hospital and Department of Medicine of The University of Sydney, Camperdown, NSW, Australia. lynda@diab.rpa.cs.nsw.gov.au
M I Constantino
M McGill
R Zilkens
D K Yue
University of Sydney · AURoyal Prince Alfred Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo construct dose response curves relating the development of diabetic complications (retinopathy and microalbuminuria) to mean glycaemic exposure in a cohort of Type 2 patients followed over a period of several years. This allows a comparison with similar data on Type 1 subjects reported by the Diabetes Control and Complications Trial (DCCT) and provides a rational basis for deciding what levels of glycaemic control should be aimed for in advising individual patients and in setting guidelines for conducting health services. RESEARCH DESIGN AND

methodsThis was an analysis of data prospectively collected in our computerized data base for Type 2 patients who attended and were followed up at the Complications Assessment Service of our Diabetes Center. The initial development of retinopathy and microalbuminuria was analyzed with respect to the mean HbA1c during the follow up period. Statistical procedures identical to those employed in the DCCT were used to construct the dose response curve.

resultsA smooth relationship between the development of retinopathy with increasing hyperglycaemia was found. For every 10% decrease in HbA1c, there was a 24%) (confidence interval (CI): 16-32) reduction in relative risk, about 2/3 of that reported for insulin-dependent diabetes mellitus (IDDM) patients. The relationship between microalbuminuria and HbAc was more linear and less steep with a relative risk reduction of 9% (CI: -2-19%) for any 10% fall in HbA1c, about 1/3 of that reported for IDDM subjects. No threshold of HbA1c can be found for the relative risk of developing complications. However, more cases of complications are prevented by the same degree of improvement in glycaemic control at higher levels of HbA1c.

conclusionsThe development of diabetic retinopathy in Type 2 subjects is also related to the magnitude of hyperglycaemia although the degree of dependence is less than that in Type 1. Glycaemic control has less influence on microalbuminuria in Type 2. In terms of relative risk, no threshold of 'safe HbA1c' can be found but in absolute terms more cases of diabetic complications can be prevented by improving the glycaemic control of the very hyperglycaemic patients.

Indexed as

AlbuminuriaBlood GlucoseDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetic RetinopathyGlycated HemoglobinHumansProspective StudiesRadioimmunoassayRisk FactorsBlood GlucoseGlycated Hemoglobin

Identifiers

PMID9886743
OpenAlexW2087907283

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.